Greek patients are waiting close to two years on average to gain access to new medicines, while an increasing number of pharmaceutical companies are reportedly choosing not to launch innovative treatments in the country at all, according to new industry data.
Findings presented by the Hellenic Association of Pharmaceutical Companies (SFEE) and data analytics firm IQVIA show that Greece continues to lag behind much of Europe in both the availability and speed of access to new therapies, particularly in areas such as cancer care, rare diseases and chronic conditions.
Between 2021 and 2024, the European Medicines Agency approved 168 new medicines, yet only 69 have reached the Greek market. Of those, just 36 are fully reimbursed and freely accessible to patients. The remainder are available only through restricted pathways, leaving Greek patients with full access to only about one in five new treatments.
A separate analysis covering 214 newly approved medicines from 2022 to 2025 found an even starker picture, with only around 20 percent currently available in Greece.
“Three out of five innovative medicines will not be available in the coming years to Greek patients,” said SFEE president Olympios Papadimitriou, warning that limited treatment options could have serious consequences for patients with cancer, blood disorders and rare diseases.
Delays remain a major concern. It takes an average of 641 days for a new medicine to move from European approval to reimbursement in Greece, compared with 158 days in Germany, 363 days in Austria and 441 days in Italy. The European average stands at 597 days.
The study also shows that Greece’s overall availability rate for new medicines is 41 percent, below the European average of 45 percent and far behind Germany at 93 percent.
Researchers say the situation is worsening. Data indicates that 62 percent of new medicines introduced in recent years are now expected never to reach the Greek market, up from 49 percent previously. Even among medicines already priced in Greece, only a small fraction are expected to remain accessible in the future.
Pharmaceutical companies point to Greece’s financial framework as a key barrier, particularly compulsory clawback and rebate mechanisms designed during the country’s debt crisis. Industry representatives argue that while these measures once aimed to control excessive spending, they are now discouraging companies from launching new treatments.
“We are victims of the Memoranda,” said SFEE director general Michalis Cheimonas, calling for a more stable and transparent pharmaceutical spending system supported by stronger digital controls and clearer budgeting.
Concerns are also rising over proposed changes to Greece’s reference pricing system, which could extend waiting times for new medicines by several months.
Across Europe, access to innovation remains uneven. While the EU approves new therapies centrally, national reimbursement systems ultimately determine availability, creating wide disparities between countries.
For patients in Greece, however, the issue remains urgent and personal: whether life-changing treatments will arrive in time to make a difference.
